Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma

Background. In the Russian Federation, in 2018 3,207 new cases of Hodgkin’s lymphoma (HL) were detected, mainly in adults. Despite significant advances in the treatment of this disease, approximately 20–30 % of patients develop relapses. High-dose chemotherapy with autologous hematopoietic stem cell...

Full description

Saved in:
Bibliographic Details
Main Authors: N. A. Avxentyev, E. M. Pazuhina, G. S. Tumyan, P. A. Zeynalova
Format: Article
Language:Russian
Published: ABV-press 2020-12-01
Series:Онкогематология
Subjects:
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/449
Tags: Add Tag
No Tags, Be the first to tag this record!